Clinical trial
Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
NCT02352935 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
- Lead sponsor
- Fuda Cancer Hospital, Guangzhou
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 1, 2015
- Completion date
- January 1, 2021
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic carcinoma